New hope for liver cancer patients after immunotherapy fails
NCT ID NCT04588051
Summary
This study is testing the drug cabozantinib for people with advanced liver cancer (hepatocellular carcinoma) whose tumors have continued to grow despite treatment with immunotherapy drugs called checkpoint inhibitors. The goal is to see if cabozantinib can slow or stop the cancer's progression and help patients live longer. Researchers will monitor how well the drug works and its side effects in about 20 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASAN Medical Center
Seoul, South Korea
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.